[Pre-Aug 2018] IMSCAR
- Published
Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
Hughes, D., Hughes, D. A. & Dubois, D., 1 Jan 2004, In: Pharmacoeconomics. 22, 16, p. 1047-1059Research output: Contribution to journal › Article › peer-review
- Published
Pharmacogenetic tests: the need for a level playing field
Hughes, D., Pirmohamed, M. & Hughes, D. A., 1 Jan 2013, In: Nature Reviews Drug Discovery. 12, 3-4Research output: Contribution to journal › Article › peer-review
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population
Hughes, D., Mulhern, B., Rowen, D., Snape, D., Jacoby, A., Marson, T., Hughes, D. A., Baker, G. & Brazier, J., 1 Jul 2014, In: Epilepsy and Behavior. 36, p. 12-17Research output: Contribution to journal › Article › peer-review
- Published
Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.
Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Pharmacoeconomic evaluations in Ireland, Scotland and Wales: A Celtic perspective on pharmaceutical assessment
Hughes, D., Hughes, D. A., Drummond, M., Tolley, K. & Ryan, M., 1 Oct 2007.Research output: Contribution to conference › Paper
- Published
Investigating factors influencing user choices to visit either general practitioners or community pharmacists in the management of minor ailments - piloting a discrete choice experiment
Hughes, D., Myles, S., Hughes, D. A., Longo, M. & Lisles, C., 1 Jun 2006.Research output: Contribution to conference › Paper
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
Cost-utility analysis of on-demand rabeprazole and esomeprazole for non-erosive reflux disease
Hughes, D. & Hughes, D. A., 1 Nov 2003.Research output: Contribution to conference › Paper
- Published
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Dec 2012, In: Value in Health. 15, 8, p. 1162-1171Research output: Contribution to journal › Article › peer-review
- Published
Rationing of drugs for rare diseases
Hughes, D. & Hughes, D. A., 1 Apr 2006.Research output: Contribution to conference › Paper
- Published
Less is more: Medicines that require less frequent administration improve adherence, but are they better?
Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 3, p. 211-213Research output: Contribution to journal › Article › peer-review
- Published
Rationing of drugs for rare diseases.
Hughes, D. & Hughes, D. A., 1 Jan 2006, In: Pharmacoeconomics. 24, 4, p. 315-316Research output: Contribution to journal › Article › peer-review
- Published
The economics of evergreening.
Hughes, D. & Hughes, D. A., 1 Jan 2009.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
A systematic review and empirical analysis of the relation between dose and duration of drug action.
Hughes, D., Hughes, D. A. & Aronson, J. K., 1 Jan 2009, p. TP40.Research output: Contribution to conference › Paper
- Published
All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.
Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Orphan drugs revisited: author's response.
Hughes, D. & Hughes, D. A., 1 May 2006, In: Quarterly Journal of Medicine. 99, 5, p. 350-351Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Hughes, D. & Hughes, D. A., 1 Mar 2010, In: Clinical Pharmacology and Therapeutics. 87, 3, p. 257-261Research output: Contribution to journal › Article › peer-review
- Published
Understanding medication compliance and persistence from an economics perspective
Hughes, D., Elliot, R. A., Shinogle, J. A., Peele, P., Bhosle, M. & Hughes, D. A., 1 Jan 2008, In: Value in Health. 11, 4, p. 600-610Research output: Contribution to journal › Article › peer-review
- Published
Welsh Health Economics Network (WHEN): Scoping Report.
Hughes, D., Farr, A., O Ceilleachair, A., Cohen, D., Hughes, D. A. & Phillips, C., 1 Jan 2005, 2005 ed. Unknown.Research output: Book/Report › Commissioned report
- Published
Development of an economic model to evaluate the cost-effectiveness of rival therapies for treating Crohn’s disease.
Hughes, D., Kikuchi, T., Bodger, K. & Hughes, D. A., 1 Jan 2008, 2008 ed. Unknown.Research output: Book/Report › Commissioned report